AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04828343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.
Study NCT04828343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.
Study NCT04856813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy active
Description: massage or ischemic compression with active contraction, tha will be isometric or concentric.
Study NCT06206174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-814
Description: Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
Study NCT04856813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: massage or isquemic compression without contraction
Study NCT06517199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine 2.5 MG
Description: olanzapine 2.5 mg/day for 28 days
Study NCT06517199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine 5 MG
Description: olanzapine 5 mg/day for 28 days
Study NCT06517199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 1 tab/day for 28 days
Study NCT04908618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital impression for normal abutment
Description: Accuracy of scan body impression
Study NCT04739514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises for dysphagia rehabilitation
Description: Diet modifications, postural exercises, compensatory exercises, swallowing exercises
Study NCT06205888 — intervention group
Intervention type: OTHER
Intervention: 18F-LNC1007（18F-FAPI-RGD） PET/CT和18F-FDG PET/CT
Description: Eligible subjects will receive 18F-LNC1007 (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT examinations within 1 week (the interval between the two examinations shall not exceed 7 days, and the scanning parameters, scanning range, image reconstruction methods, etc., shall be consistent). That is, with 18F-LNC1007 (18F-FAPI-RGD) PET/CT time as D0, 18F-FDG PET/CT examination can accept data from D1 to D7
Study NCT06539013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: remifentanil infusion
Study NCT06539013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N2O
Description: Use of N2O for analgesia
Study NCT06539013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Use of Fentanylfor analgesia
Study NCT04795232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COD45
Description: Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
Study NCT04795232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COD90
Description: Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
Study NCT05386355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine Uptake App
Description: A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.
Study NCT05386355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Health App
Description: A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.
Study NCT05208151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Creative Drama Education
Description: Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
Study NCT05632887 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06011148 — intervention group
Intervention type: DEVICE
Intervention: Perceval S sutureless heart valve
Description: Aortic Valve Replacement with Perceval S sutureless heart valve
Study NCT05030012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Control
Description: The purpose of this intervention is to evaluate that the efficacy and safety during the automated performance of the Vapotherm OAM are not inferior to standard care practice (manual control) in maintaining SpO2 levels of 90-95% in preterm infants requiring oxygen adjustments while being treated with high velocity nasal insufflation (HVNI) therapy.
Study NCT05030012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Control
Description: The purpose of this intervention is to establish an active comparator via standard care practice against which to evaluate the efficacy and safety of the automated arm of the study, for determination of non-inferiority of that automated control arm to manual control in maintaining SpO2 levels of 90-95% in preterm infants being treated with high velocity nasal insufflation (HVNI) therapy.
Study NCT05365503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shamiri Intervention
Description: The first two sessions focus on the concept of growth mindset, the third session focuses on gratitude, and the fourth and final session focuses on values. In session one, participants are guided through a Growth mindset intervention designed to convey the idea that people and their situations can change for the better. In session two, group leaders introduce a discussion and activities about effective strategies for growth. Then, the group leaders introduce a framework for problem solving. In session three, group leaders emphasize the importance of verbalizing and consciously thinking about Gratitude, as well as its benefits for well-being. In the final session, participants are introduced to the concept of values. Participants discuss stories of culturally pertinent role models, with an emphasis on the values these individuals display, and how their values guided their life decisions and led to success and happiness.
Study NCT04797559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SZMN Block
Description: Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally near the temples of the patient
Study NCT06517004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR201
Description: Autologous CD19/CD20-directed CAR-T cells, single infusion intravenously
Study NCT05687669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
Description: Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
Study NCT05094388 — intervention group
Intervention type: OTHER
Intervention: Admitted to intensive care units
Description: Admitted to intensive care units
Study NCT05150899 — intervention group
Intervention type: DRUG
Intervention: Tamsulosin Hcl 0.4Mg Cap
Description: alpha blocker
Study NCT06320561 — intervention group
Intervention type: OTHER
Intervention: Longitudinal prospective cohort study
Description: Patients after stroke who meet the in- and exclusion criteria will be examined 4 times during the first 3 months after their stroke.
Study NCT05150899 — intervention group
Intervention type: DRUG
Intervention: fexofenadine 180 mg Oral tablet
Description: antihistaminic
Study NCT04697680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm 1
Description: A sleep extension algorithm (algorithm 1) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
Study NCT04697680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm 2
Description: A sleep extension algorithm (algorithm 2) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
Study NCT04697680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm 3
Description: A sleep extension algorithm (algorithm 3) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
Study NCT04800172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: administration of roflumilast 500 mcg tablet once daily for 3 months.
Study NCT06220539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casting and supervised rehabilitation
Description: casting (8 weeks) followed by supervised rehabilitation
Study NCT04800172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of placebo tablet once daily for 3 months.
Study NCT06083064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal imaging
Description: Abdominal ultrasound and/or abdominal CT
Study NCT06083064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Score based selective abdominal imaging
Description: Abdominal imaging is done selectively based on Adult Appendicitis Score
Study NCT06083064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Score based selective observation combined with selective abdominal imaging
Description: Observation based on Appendicitis Severity Score combined Adult Appendicitis Score based selective abdominal imaging
Study NCT05756075 — intervention group
Intervention type: BEHAVIORAL
Intervention: Aerobic exercise training
Description: Participants will follow a personalized aerobic exercise training program twice a week at the physiotherapist. The intensity of the program is based on the results of the 6MWT according to the most recent guidelines for physiotherapy for PD and COPD
Study NCT06073145 — intervention group
Intervention type: DEVICE
Intervention: conventional transcranial Doppler probe and wearable ultrasound patch.
Description: Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
Study NCT05273671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
Study NCT05273671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
Study NCT05273671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: will receive with a saline solution 10 min before the end of surgery
Study NCT05246358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChoniSense Polso
Description: A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study.
Study NCT06385626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raspberry leaf tea
Description: 10 g of raspberry leaf tea
Study NCT06385626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry leaf tea
Description: 10 g of raspberry leaf tea
Study NCT05773170 — intervention group
Intervention type: DRUG
Intervention: Refralon
Description: 1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
Study NCT05825352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carmellose eye drops
Description: Ocular drops based upon carmellose
Study NCT04989283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT04989283 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04989283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT05346666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
Description: Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
Study NCT05346666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
Description: Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
Study NCT06024642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V117957
Description: V117957 1 mg - 1 tablet taken orally at bedtime.
Study NCT06024642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Study NCT05304351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Antigen High Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
Study NCT05304351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Antigen Low Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
Study NCT05304351 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
Study NCT05304351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Adjuvant High Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
Study NCT05304351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Adjuvant Middle Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
Study NCT05304351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Adjuvant Low Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
Study NCT06536660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnesium bone plate and screw fixation in jaw surgery
Description: Participants will undergo jaw surgery based on their clinical indications. High-purity magnesium bone plates and screws will be used for internal fixation during the surgical procedure.
Study NCT05681507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block
Description: Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.
Study NCT05681507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative analgesia
Description: Standard of postoperative ICU analgesic care, per institutional protocol
Study NCT04909073 — intervention group
Intervention type: DRUG
Intervention: Afatinib
Description: Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
Study NCT04753073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive physical plasma
Description: Treatment with non invasive physical low-temperature plasma
Study NCT05940792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonelastic taping
Description: Non-elastic taping was placed on the ankle of the affected side with a plaster band starting from the middle of the sole of the foot and extending from the lateral side of the foot to the level below the knee to provide eversion support.
Study NCT05940792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physiotherapy
Description: The conventional physiotherapy programme included range of motion exercises, balance and gait training and neuromuscular electrical stimulation.
Study NCT04599634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.
Study NCT06323109 — intervention group
Intervention type: DEVICE
Intervention: MRI-UDS; US-UDS; MCUD
Description: Imaging procedures will include a comprehensive protocol of dynamic MRI, 3D ultrasound and MCUD to evaluate and validate this entirely novel methodology.
Study NCT04599634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: For FL patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL, MCL or CLL patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
Study NCT05470127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate biopsy needle
Description: Prostate tissue biopsy with a biopsy needle
Study NCT05470127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy needle
Description: Prostate tissue biopsy with a biopsy needle